Close Menu

This article has been updated to correctly represent the interim survival analysis for patients who cleared ctDNA at any point after treatment. 

NEW YORK – Researchers have demonstrated in a Phase II study that customized circulating tumor DNA (ctDNA) assays designed by genetic testing firm Natera could potentially be useful for monitoring whether patients with a variety of cancers will respond to immunotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.